Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start

Vivani Medical, Inc.

NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.
Phase 1 study expected to start H1 2026 pending regulatory clearance; designed for safety, tolerability, PK.
Phase 2 dose-ranging study planned to follow Phase 1, pending enabling results and regulatory feedback.
NPM-139 aims to deliver Wegovy-level efficacy with once or twice-yearly administration.
Positive preclinical data and promising LIBERATE-1 results for NPM-115 (exenatide) support program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.